SCHEMBL8913617

SCHEMBL8913617

CC1(NC=O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445949 0.94
SCHEMBL11923811 0.92 HDAC3 (0.30)
SCHEMBL13075601 0.92 HDAC3 (0.30)
SCHEMBL8113051 0.88
SCHEMBL16828905 0.77 KDM4E (0.33)
SCHEMBL3936436 0.75
SCHEMBL11923812 0.75 LMNA (0.38)
SCHEMBL3939744 0.71
SCHEMBL1458379 0.70
SCHEMBL15213164 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002324-A1 NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS PTC THERAPEUTICS, INC. 2023-01-05 US disclosed
WO-2020252414-A1 NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS PTC THERAPEUTICS, INC. (US) 2020-12-17 WO disclosed
CN-110461838-A oxadiazole transient receptor potential channel inhibitors HOFFMANN LA ROCHE 2019-11-15 CN disclosed
WO-2016096721-A1 PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-23 WO disclosed
US-5633364-A N4 -substituted 2'-deoxycytidine compounds, oligonucleotides including N4 -labeled 2'-deoxycytidines, and a process for making oligonucleotides with N-modified 2'-deoxycytidines AMOCO CORPORATION (US) 1997-05-27 US disclosed
US-5405950-A N4 -substituted cytidines and process for incorporation into an oligonucleotides AMOCO CORPORATION (US) 1995-04-11 US disclosed